Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2371 AL 2385

The potential role of Keap1-Nrf2 pathway in the pathogenesis of Alzheimer's disease, type 2 diabetes, and type 2 diabetes-related Alzheimer's disease

He L, Sun Y.

Metab Brain Dis. 2021 Oct;36(7):1469-1479. doi: 10.1007/s11011-021-00762-z. Epub 2021 Jun 15.

Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease

Matthews DC, Mao X, Dowd K, Tsakanikas D, Jiang CS, Meuser C, Andrews RD, Lukic AS, Lee J, Hampilos N, Shafiian N, Sano M, David Mozley P, Fillit H, McEwen BS, Shungu DC, Pereira AC.

Brain. 2021 Dec 31;144(12):3742-3755. doi: 10.1093/brain/awab222.

Chronic stress and Alzheimer's disease

Mohammadi S, Zandi M, Dousti Kataj P, Karimi Zandi L.

Biotechnol Appl Biochem. 2022 Aug;69(4):1451-1458. doi: 10.1002/bab.2216. Epub 2021 Jul 5.

Physical exercise is effective for neuropsychiatric symptoms in Alzheimer's disease: a systematic review

Mendonça DCB, Fernandes DR, Hernandez SS, Soares FDG, Figueiredo K, Coelho FGM.

Arq Neuropsiquiatr. 2021 May;79(5):447-456. doi: 10.1590/0004-282X-ANP-2020-0284.

Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium

Singulani MP, De Paula VJR, Forlenza OV.

Neurosci Lett. 2021 Aug 24;760:136078. doi: 10.1016/j.neulet.2021.136078. Epub 2021 Jun 20.

Mechanistic perspectives on differential mitochondrial-based neuroprotective effects of several carnitine forms in Alzheimer's disease in vitro model

Mota SI, Pita I, Águas R, Tagorti S, Virmani A, Pereira FC, Rego AC.

Arch Toxicol. 2021 Aug;95(8):2769-2784. doi: 10.1007/s00204-021-03104-1. Epub 2021 Jun 24.

Safety and Pharmacokinetics of HTL0018318, a Novel M(1) Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects

Bakker C, van der Aart J, Labots G, Liptrot J, Cross DM, Klaassen ES, Dickinson S, Tasker T, Groeneveld GJ.

Drugs R D. 2021 Sep;21(3):295-304. doi: 10.1007/s40268-021-00352-5. Epub 2021 Jun 23.

Senotherapeutics: Targeting senescent cells for the main age-related diseases

Boccardi V, Mecocci P.

Mech Ageing Dev. 2021 Jul;197:111526. doi: 10.1016/j.mad.2021.111526. Epub 2021 Jun 21.

Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's

Butler T, Goldberg JD, Galvin JE, Maloney T, Ravdin L, Glodzik L, de Leon MJ, Hochman T, Bowen RL, Atwood CS.

Contemp Clin Trials. 2021 Aug;107:106488. doi: 10.1016/j.cct.2021.106488. Epub 2021 Jun 22.

Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer's: a Comprehensive Review

Eskandari S, Sajadimajd S, Alaei L, Soheilikhah Z, Derakhshankhah H, Bahrami G.

Neurotox Res. 2021 Oct;39(5):1589-1612. doi: 10.1007/s12640-021-00381-7. Epub 2021 Jun 25.

O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature

Bartolomé-Nebreda JM, Trabanco AA, Velter AI, Buijnsters P.

Expert Opin Ther Pat. 2021 Dec;31(12):1117-1154. doi: 10.1080/13543776.2021.1947242. Epub 2021 Jul 8.

Pharmacological relevance of CDK inhibitors in Alzheimer's disease

Malhotra N, Gupta R, Kumar P.

Neurochem Int. 2021 Sep;148:105115. doi: 10.1016/j.neuint.2021.105115. Epub 2021 Jun 25.

The role of extracellular matrix alterations in mediating astrocyte damage and pericyte dysfunction in Alzheimer's disease: A comprehensive review

Anwar MM, Özkan E, Gürsoy-Özdemir Y.

Eur J Neurosci. 2022 Nov;56(9):5453-5475. doi: 10.1111/ejn.15372. Epub 2021 Jul 5.

A carte blanche approval in Alzheimer's

Nat Biotechnol. 2021 Jul;39(7):781. doi: 10.1038/s41587-021-00995-4.

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer's disease

Latimer CS, Liachko NF.

Geroscience. 2021 Aug;43(4):1627-1634. doi: 10.1007/s11357-021-00407-0. Epub 2021 Jun 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias